Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rFlu-huCTLA4
- Development stage
- Unknown
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intratumoral, Intravenous, Potentially Other Parenteral (preclinical—precise Human Routes Unconfirmed)
01
Overview
rFlu-huCTLA4 is a recombinant, chimeric oncolytic influenza A virus engineered to express a human CTLA4 antibody. It acts as an oncolytic virus—in other words, it selectively infects and destroys cancer cells—while locally delivering a checkpoint inhibitor (anti-CTLA4 antibody) to enhance anti-tumor immune responses. In preclinical models, rFlu-huCTLA4 demonstrated the ability to selectively kill hepatocellular carcinoma cells, induce apoptosis in tumor cells, and significantly activate T cells (both CD4^+^ and CD8^+^ T cells), leading to potent anti-tumor immunity. The backbone virus is derived from the A/PR/8/34 (PR8) influenza strain. rFlu-huCTLA4 is currently being studied for its efficacy in hepatocellular carcinoma and shows potential as a novel local/regional immunotherapy approach in oncology[2].
- Brand names
- rFlu-CTLA4rFlu-CTLA-4rFlu-CTLA 4
- Other names
- rFlu-huCTLA4rFlu-huCTLA-4rFlu-huCTLA 4
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on rFlu-huCTLA4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rFlu-huCTLA4.